GDF15 and breast carcinoma: Thus, our data in the breast cancer space suggest that GDF15 should be considered as a possible therapeutic co-target to eradicate or prevent the development of DTP cells during treatment with eribulin in both TNBC and luminal breast cancer subtypes.